Literature DB >> 3184276

Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge.

R M Kinney1, J J Esposito, J H Mathews, B J Johnson, J T Roehrig, A D Barrett, D W Trent.   

Abstract

Mice immunized with recombinant vaccinia virus (VACC) expressing Venezuelan equine encephalitis (VEE) virus capsid protein and glycoproteins E1 and E2 or with attenuated VEE TC-83 virus vaccine developed VEE-specific neutralizing antibody and survived intraperitoneal challenge with virulent VEE virus strains including Trinidad donkey (subtype 1AB), P676 (subtype 1C), 3880 (subtype 1D), and Everglades (subtype 2). However, unlike immunization with TC-83 virus, immunization with the recombinant VACC/VEE virus did not protect mice from intranasal challenge with VEE Trinidad donkey virus. These results suggest that recombinant VACC/VEE virus is a vaccine candidate for equines and humans at risk of mosquito-transmitted VEE disease but not for laboratory workers at risk of accidental exposure to aerosol infection with VEE virus.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3184276      PMCID： PMC253584     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  49 in total

1.  Venezuelan equine encephalomyelitis in horses.

Authors:  R E KISSLING; R W CHAMBERLAIN; D B NELSON; D D STAMM
Journal:  Am J Hyg       Date:  1956-05

2.  Venezuelan equine encephalomyelitis due to vaccination in man.

Authors:  L S SUTTON; C C BROOKE
Journal:  J Am Med Assoc       Date:  1954-08-21

3.  The role of the olfactory route on infection of the respiratory tract with Venezuelan equine encephalomyelitis virus in normal and operated Macaca rhesus monkeys. I. Results of virological examination.

Authors:  L Danes; J Kufner; J Hrusková; V Rychterová
Journal:  Acta Virol       Date:  1973-01       Impact factor: 1.162

4.  Recovery of Venezuelan equine encephalomyelitis virus in Panama. A fatal case in man.

Authors:  K M Johnson; A Shelokov; P H Peralta; G J Dammin; N A Young
Journal:  Am J Trop Med Hyg       Date:  1968-05       Impact factor: 2.345

5.  Proposed antigenic classification of registered arboviruses I. Togaviridae, Alphavirus.

Authors:  C H Calisher; R E Shope; W Brandt; J Casals; N Karabatsos; F A Murphy; R B Tesh; M E Wiebe
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

6.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

7.  Experimental studies of rhesus monkeys infected with epizootic and enzootic subtypes of Venezuelan equine encephalitis virus.

Authors:  T P Monath; C H Calisher; M Davis; G S Bowen; J White
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

8.  Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies.

Authors:  J Esposito; K Brechling; G Baer; B Moss
Journal:  Virus Genes       Date:  1987-11       Impact factor: 2.332

9.  Expression of Sindbis virus structural proteins via recombinant vaccinia virus: synthesis, processing, and incorporation into mature Sindbis virions.

Authors:  C M Rice; C A Franke; J H Strauss; D E Hruby
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

10.  Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis.

Authors:  R Ramphal; R C Cogliano; J W Shands; P A Small
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441
View more
  17 in total

1.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses.

Authors:  Y S Hahn; E M Lenches; R Galler; C M Rice; J Dalrymple; J H Strauss
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Authors:  Gabriel N Defang; Dimple Khetawat; Christopher C Broder; Gerald V Quinnan
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

4.  Protection from La Crosse virus encephalitis with recombinant glycoproteins: role of neutralizing anti-G1 antibodies.

Authors:  A Pekosz; C Griot; K Stillmock; N Nathanson; F Gonzalez-Scarano
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

5.  Positively charged amino acid substitutions in the e2 envelope glycoprotein are associated with the emergence of venezuelan equine encephalitis virus.

Authors:  Aaron C Brault; Ann M Powers; Edward C Holmes; C H Woelk; Scott C Weaver
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.

Authors:  I J Caley; M R Betts; D M Irlbeck; N L Davis; R Swanstrom; J A Frelinger; R E Johnston
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.

Authors:  N L Davis; K W Brown; R E Johnston
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus.

Authors:  Nadezhda E Yun; Bi-Hung Peng; Andrea S Bertke; Viktoriya Borisevich; Jennifer K Smith; Jeanon N Smith; Allison L Poussard; Milagros Salazar; Barbara M Judy; Michele A Zacks; D Mark Estes; Slobodan Paessler
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

Review 9.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

10.  Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein.

Authors:  R M Kinney; G J Chang; K R Tsuchiya; J M Sneider; J T Roehrig; T M Woodward; D W Trent
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.